Participant flow

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas · Source last updated 2021-11-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

   id

   FG000

   title

   A+CHP

2. description

   cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

   id

   FG001

   title

   CHOP

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         22

      2. group Id

         FG001

         num Subjects

         16

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         5

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         68

      2. group Id

         FG001

         num Subjects

         89

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Not eligible, no study drug received

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Change of diagnosis

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         226

      2. group Id

         FG001

         num Subjects

         226

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         131

      2. group Id

         FG001

         num Subjects

         116

      comment

      Completed due to study closure by sponsor

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         95

      2. group Id

         FG001

         num Subjects

         110

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Jan2013-Nov2016

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice